Bladder Cancer
Kidney Cancer
EAU Edu Platform on Prostate Cancer
Home
Articles
Article of the Month
Editorial
Videos
Webcasts
Education
Online curriculum
E-courses
ESOU Online
Webinars
Guidelines
Events
Home
Articles
Terug
Article of the Month
Editorial
Videos
Webcasts
Education
Terug
Online curriculum
E-courses
ESOU Online
Webinars
Guidelines
Events
Upcoming event
ESU-ESUI Masterclass on Prostate biopsy
Home
/
Article of the Month
Back
Tag:
Article of the Month
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials
View
Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer
View
Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial
View
Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
View
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
View
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
View
How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires
View
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
View
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
View
Diagnostic Performance of 68 Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate Cancer
View